Summit Therapeutics (NasdaqGM:SMMT) Q4 2025 Earnings call February 23, 2026 04:30 PM ET Company ParticipantsAllen Yang - Chief R&D Strategy OfficerDave Gancarz - Chief Business and Strategy OfficerJosh Schimmer - Senior Managing Director and Leader in Biotechnology Equity ResearchMaky Zanganeh - Co-CEO and PresidentManmeet S. Soni - COO and CFOMark Schwartz - Vice ChairmanRobert Duggan - Co-Chief Executive Officer and Chairman of the BoardConference Call ParticipantsAsthika Goonewardene - Managing Director ...

Financial Data and Key Metrics Changes - The company ended 2025 with a strong cash position of approximately $713.4 million, with no debt [30] - Total GAAP operating expenses for Q4 2025 were $225 million, a decrease from $234.2 million in Q3 2025, primarily due to lower stock-based compensation expenses [30][31] - Non-GAAP operating expenses for Q4 2025 were $113.3 million, an increase from $103.4 million in Q3 2025, mainly driven by increased R&D expenses related to clinical trials [31] Business Line Data and Key Metrics Changes - The HARMONi-3 study for ivonesimab has completed screening for the squamous cohort, with the last patient expected to be randomized soon [8] - The company has announced an interim PFS analysis for the squamous cohort of HARMONi-3, planned for Q2 2026 [10][29] - The ILLUMINE study, a new Phase III trial in head and neck cancer, is expected to begin enrollment early next quarter [11] Market Data and Key Metrics Changes - Over 60,000 patients in China have received ivonesimab based on two approved indications, with a third indication currently under review [16] - The total addressable market for ivonesimab is estimated to exceed $100 billion globally, with significant potential in multiple tumor types [27] Company Strategy and Development Direction - The company is focused on expanding its clinical development plan and preparing for commercialization, anticipating a decision from the FDA on its BLA by the end of 2026 [7][19] - The strategy includes leveraging positive data from previous trials to accelerate discussions with regulatory agencies [36][55] - The company aims to expand its footprint in the oncology market, particularly in non-small cell lung cancer, by utilizing synergies across different patient populations [80] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the potential of ivonesimab, citing positive data from previous trials and the need for effective treatments in oncology [19][27] - The company is preparing for a potential commercial launch in anticipation of FDA approval, ramping up commercial capabilities [32] - Management emphasized the importance of interim analyses to facilitate earlier discussions with regulatory bodies [36][55] Other Important Information - The company has initiated multiple collaborations, including with GSK and Revolution Medicines, to explore new treatment combinations [14][23] - A total of 15 Phase III trials are ongoing or have been announced, demonstrating the company's commitment to expanding its clinical research [17] Q&A Session Summary Question: What drove the decision to include the interim PFS analysis for HARMONi-3? - The decision was based on positive results from previous studies (HARMONi-2 and HARMONi-6) and the desire to accelerate timelines for regulatory discussions [36][37] Question: Was there anything specific in HARMONi-3 that increased confidence for the interim analysis? - The decision was data-backed, influenced by the positive outcomes from HARMONi-2 and HARMONi-6, rather than new information from HARMONi-3 [42][43] Question: What signals will be used to consider expanding into the U.S. for the head and neck study? - Enthusiasm from enrollment and feedback from the cooperative group, along with data from ongoing studies, will guide the decision [61][67]

Financial Data and Key Metrics Changes - The company ended 2025 with a strong cash position of approximately $713.4 million, with no debt [29] - Total GAAP operating expenses for Q4 2025 were $225 million, a decrease from $234.2 million in Q3 2025, primarily due to lower stock-based compensation expenses [30] - Non-GAAP operating expenses for Q4 2025 were $113.3 million, an increase from $103.4 million in Q3 2025, mainly driven by increased R&D expenses related to clinical trials [31] Business Line Data and Key Metrics Changes - The HARMONi-3 study for ivonesimab has completed screening for the squamous cohort, with the last patient expected to be randomized soon [7] - The company has announced an interim PFS analysis for the squamous cohort of HARMONi-3, planned for Q2 2026 [9] - The ILLUMINE study, evaluating ivonesimab in head and neck cancer, is set to begin enrollment early next quarter [10] Market Data and Key Metrics Changes - Over 60,000 patients in China have received ivonesimab based on two approved indications, with a third indication currently under review [14] - The total addressable market for ivonesimab is estimated to exceed $100 billion globally, with potential improvements over current standard of care [26] Company Strategy and Development Direction - The company is focused on expanding its clinical development plan and preparing for commercialization, anticipating a decision from the FDA on its BLA by the end of the year [6] - The strategy includes ramping up commercial capabilities in anticipation of potential launch and expanding into additional settings with multiple collaborations [20][21] - The company aims to leverage positive data from ongoing trials to accelerate discussions with regulatory agencies [56] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the potential of ivonesimab based on positive data from previous trials, emphasizing the importance of bringing the treatment to patients as soon as possible [44] - The company is optimistic about the upcoming interim PFS analysis and believes it will facilitate earlier discussions with the FDA regarding the drug's approval [59] Other Important Information - The company has initiated 44 clinical trials since 2019, with over 4,000 patients enrolled globally [13] - The company has entered into collaborations with Revolution Medicines and GSK to evaluate ivonesimab in combination with novel therapies [21][22] Q&A Session All Questions and Answers Question: What drove the decision to include the interim PFS analysis for HARMONi-3? - The decision was based on positive results from HARMONi-2 and HARMONi-6, allowing for earlier discussions with regulatory agencies [36] Question: Was there anything specific in HARMONi-3 that increased confidence for the interim analysis? - The decision was data-backed, influenced by the positive interim readouts from HARMONi-2 and HARMONi-6 [42] Question: What gives confidence that positive PFS data will translate to OS benefits? - The company highlighted the consistency of results across multiple studies, with a strong correlation between PFS and OS benefits observed in similar trials [72] Question: How much of the commercial footprint for EGFR mutant non-small cell lung cancer will be usable for the broader squamous population? - The company indicated that there are significant synergies in the commercial footprint, as many physicians treat both populations [81]

Group 1 - Summit Therapeutics (NASDAQ:SMMT) is identified as one of the 17 biotechnology stocks with more than 50% upside potential, with a projected median 1-year price target of $57.98, indicating a strong upside of over 296% [1] - The U.S. FDA has accepted Summit Therapeutics' application for ivonescimab, a lung cancer treatment, with a decision date set for November 14, 2026, based on data from the global phase III HARMONi trial [2][4] - The application targets a market gap for approximately 14,000 eligible U.S. patients annually and is supported by a partnership with Akeso for commercial exposure in China, positioning the company for potential entry into the U.S. oncology market [3] Group 2 - Summit Therapeutics is a clinical-stage biopharmaceutical company focused on developing ivonescimab, a bispecific antibody that combines PD-1 blockade and anti-angiogenesis in a single molecule, and is currently conducting Phase III clinical trials for non-small cell lung cancer [4]

Core Viewpoint - Akeso, Inc. has received acceptance for its supplemental New Drug Application (sNDA) for gumokimab, a novel treatment for active ankylosing spondylitis, from the National Medical Products Administration (NMPA) in China, indicating a significant step forward in addressing the needs of approximately 4 million AS patients in the country [1][4]. Group 1: Drug Development and Regulatory Progress - Gumokimab is the second indication for which Akeso has gained NDA review acceptance, following its previous acceptance for treating moderate-to-severe psoriasis in January 2025 [2]. - Gumokimab is Akeso's third non-oncology drug candidate to enter the regulatory review phase, alongside ebronucimab and ebdarokimab, showcasing the company's expanding non-oncology portfolio [3]. - The NDA acceptance for gumokimab is based on positive results from the pivotal Phase III clinical trial (AK111-303), which demonstrated effective alleviation of AS symptoms and significant improvements in patients' activity, physical function, and quality of life [4]. Group 2: Company Overview and Pipeline - Akeso is a leading biopharmaceutical company founded in 2012, focused on the research, development, manufacturing, and commercialization of innovative biological medicines, with a robust pipeline of over 50 innovative assets across various disease areas [8][9]. - The company has developed a unique integrated R&D innovation system, including the ACE Platform for drug development and Tetrabody technology for bispecific antibody development, positioning itself as a globally competitive biopharmaceutical entity [8]. - Akeso has 26 candidates in clinical trials, including 15 bispecific/multispecific antibodies, and has successfully launched 7 new drugs commercially, emphasizing its commitment to delivering affordable therapeutic antibodies [9].

Core Insights - Summit Therapeutics is poised for a transformative year in 2026, focusing on its lead asset, ivonescimab, which has shown promising results in clinical trials [1][2] Group 1: Clinical Development - Summit and its partner Akeso have completed four positive Phase III studies with ivonescimab, demonstrating its efficacy against PD-1 inhibitors and in settings where these inhibitors have failed [2] - The company believes ivonescimab holds a potential first mover status in the frontline treatment of multiple solid tumors, positioning it strongly in a market projected to exceed $100 billion annually [2] Group 2: Regulatory Progress - Summit submitted its Biologics License Application (BLA) to the FDA in Q4 2025, based on the favorable benefit-risk profile of ivonescimab demonstrated in the HARMONi study [3] - The submission is significant due to the high unmet medical need and limited treatment options available for patients in the relevant settings [3]

Summit Therapeutics FY Conference Summary Company Overview - **Company**: Summit Therapeutics (NasdaqGM:SMMT) - **Lead Asset**: Ivonescimab - **Co-CEOs**: Dr. Maky Zanganeh and Bob Duggan - **Employee Count**: Over 275 employees Industry Context - **Market Size**: The PD-1/VEGF market is estimated to exceed $100 billion annually [2][29] - **Checkpoint Inhibitor Market**: Expected to top $20 billion by 2028 for non-small cell lung cancer alone [29] Key Developments - **Phase III Studies**: Completed four positive Phase III studies for ivonescimab, both in China and globally [1][2] - **BLA Submission**: Submitted Biologics License Application (BLA) to the FDA in Q4 2025 based on positive results from the Harmony study [2][19] - **Clinical Trials**: Actively enrolling in three global Phase III trials: Harmony III, Harmony VII, and Harmony GI III [3][8] Clinical Trial Highlights - **Harmony Studies**: - **Harmony III**: Evaluating ivonescimab plus chemotherapy against pembrolizumab plus chemotherapy in frontline metastatic non-small cell lung cancer [10][11] - **Harmony VII**: Evaluating ivonescimab monotherapy against pembrolizumab monotherapy for high PD-L1 expression patients [11] - **Harmony GI III**: Evaluating ivonescimab plus chemotherapy in unresectable metastatic colorectal cancer [12] - **Positive Results**: All four Phase III trials have shown positive results, marking a significant achievement in the PD-1/VEGF class [5][20] Mechanism of Action - **Unique Design**: Ivonescimab is a bispecific antibody designed to improve safety and efficacy by targeting both PD-1 and VEGF [6][7] - **Binding Properties**: Demonstrates cooperative binding properties that enhance anti-tumor activity [6] Competitive Position - **First-Mover Advantage**: Ivonescimab holds a significant lead over competitors in the PD-1/VEGF space, with ongoing trials while others are still in early stages [9][13] - **Collaborations**: Partnerships with Akeso and other companies to expand clinical trials and data collection [8][14] Financial Position - **Cash Balance**: Raised $500 million in October 2025, bringing cash reserves to approximately $710 million, remaining debt-free [28] Future Outlook - **Regulatory Decisions**: Anticipated FDA decision on BLA submission by the end of 2026 [19][27] - **Pipeline Expansion**: Plans to introduce novel combinations and new Phase III studies in 2026 [26][27] Conclusion - **Transformative Year**: 2026 is expected to be pivotal for ivonescimab, with significant potential to impact cancer treatment and patient outcomes [29]

Summary of China Pharma and Biotech Conference Call Industry Overview - **Sector Outlook**: The China Pharma and Biotech sector is experiencing a positive outlook with valuations returning to a more rational range compared to mid-2025. Most stocks have seen a decline of 20-30%, and major healthcare indices are below 2023 post-COVID reopening levels, providing a solid base for growth in 2026 [1][10][11]. - **Growth Drivers**: Accelerated growth and quality improvement in the sector are anticipated, driven by the unique advantages of Chinese drugmakers that support globalization and sector re-rating trends [1][10]. Key Insights on China Biopharma - **R&D Efficiency**: China's early R&D model has matured, with clinical trials costing 60-70% less than in the U.S. Preclinical research averages 1.5 years, and Phase 1 trials take less than 2 years, significantly faster than global standards [2]. - **Global Pipeline Contribution**: China's share of the global biopharma pipeline has increased to 43% in 2025, up from 38% in 2024. However, the percentage of First-in-Class (FIC) drugs remains lower than in developed markets (17% vs. 37%) [2]. - **Out-licensing Trends**: The trend of outbound deals is expected to continue, with innovative models like platform deals and co-development agreements emerging. These deals are seen as avenues for revenue maximization, although they may not impact stock prices as significantly as in 2025 [2][13]. Stock-Specific Catalysts for 2026 - **Oncology Developments**: A significant number of trials (20+) in Non-Small Cell Lung Cancer (NSCLC) are expected to report data, with key players including Kelun, Innovent, and Akeso. New modalities such as multispecific antibodies and ADCs are also anticipated to provide proof of concept data [3]. - **GLP-1 Drugs**: HRS-9531 (Hengrui) and TG103 (CSPC) have submitted New Drug Applications (NDA) in the second half of 2025, with expected approvals in late 2026 or 2027 [3]. Top Stock Picks - **Innovent**: Anticipated strong sales growth for mazdutide and updates on IBI363 trials across various indications [4]. - **Kelun**: Expected to report results from its first global Phase 3 trial and domestic sales growth of approximately 40% [4]. - **Hansoh & Hengrui**: Projected recurring license income to contribute 10-15% of revenue, with net income growth of 20-30% CAGR from 2024 to 2027 [4]. Investment Ratings - **Outperform Ratings**: Hansoh, Kelun-Biotech, Innovent, and Jiangsu Hengrui are rated as outperform [6]. - **Market-Perform Ratings**: Akeso, BeOne Medicines (BeiGene), Sino Biopharm, Zai Lab, and CSPC are rated as market-perform [6]. Financial Projections - **Stock Performance**: The report includes a detailed table of stock ratings, target prices, and financial projections for various companies, indicating significant upside potential for selected stocks [5][9]. Additional Insights - **Market Dynamics**: The sector has transitioned from exuberance to equilibrium, with a notable correction in stock prices since October 2025, following a period of rapid growth [10][11]. - **Approval Trends**: The number of innovative drug approvals by the National Medical Products Administration (NMPA) has accelerated, with 69 approvals in 2025, while the FDA remains receptive to Chinese drug candidates [33]. This summary encapsulates the key points from the conference call, highlighting the positive outlook for the China Pharma and Biotech sector, the efficiency of R&D processes, stock-specific catalysts, and investment recommendations.

Summary of the Conference Call on China Healthcare and Pharmaceuticals Industry Overview - The conference focused on the **China healthcare and pharmaceuticals** sector, specifically discussing the **2025 National Reimbursement Drug List (NRDL)** and the **Commercial Health Insurance Innovative Drug Directory (CHIIDD)** [1][2]. Key Points NRDL and CHIIDD Updates - Approximately **70 innovative drugs** were included in the NRDL, with a **success rate of 88%** for new drug negotiations, an increase from **76% in 2024** [2]. - A total of **114 new drugs** were added to the NRDL, including **50 type 1 innovative drugs**, while **29 drugs** were removed, bringing the total to **3,253 drugs** [2]. - The CHIIDD features **19 expensive innovative drugs** out of **24 candidates**, covering treatments for oncology, Alzheimer’s disease, and rare diseases [2]. Implementation Timeline - The new NRDL and CHIIDD will be implemented on **January 1, 2026**, with new prices for most newly included drugs to be revealed at that time [3]. Company-Specific Insights 1. **Hengrui (600276 CH/1276 HK)**: - Included **10 new drugs** in the NRDL for the first time, such as trastuzumab rezetecan and ivarmacitinib [4]. 2. **Hansoh (3692 HK)**: - Added two new indications for almonertinib to the NRDL [4]. 3. **Sinobio (1177 HK)**: - Three new drugs added: garsorasib, recombinant human coagulation factor VIIa, and penpulimab [5]. 4. **Innovent (1801 HK)**: - New additions include teprotumumab, limertinib, and fulzerasib among others [5]. 5. **BeOne (6160 HK/ONC US)**: - Newly added dinutuximab and zanidatamab in the CHIIDD [5]. 6. **Kelun Biotech (6990 HK)**: - Included sacituzumab tirumotecan and cetuximab N01 in the NRDL [5]. 7. **Akeso (9926 HK)**: - Added new indications for ivonescimab and cadonilimab, along with ebdarokimab and ebronucimab in the NRDL [6]. 8. **Tirzepatide**: - Included in the NRDL for type 2 diabetes, but not for obesity [6]. Market Outlook - The higher success rate and supportive policy trends suggest a **bright sales outlook** for innovative drugs, which are expected to drive growth for the related companies in **2026** [7]. Additional Insights - The report emphasizes the positive implications of the NRDL updates for the growth of covered companies, indicating a favorable environment for innovative drug sales in the Chinese healthcare market [4][7].

Core Viewpoint - Summit Therapeutics and Madrigal Pharmaceuticals have shown significant stock price increases over the past three years, with Summit rising 2,280% and Madrigal gaining 631%, indicating strong clinical and regulatory advancements in the biotech sector [1][2]. Group 1: Summit Therapeutics - Summit Therapeutics is developing ivonescimab, a bispecific antibody that has shown greater efficacy than Keytruda in a phase 3 study for non-small cell lung cancer, currently undergoing further studies in the U.S. [4][5]. - The market potential for ivonescimab is substantial, with analysts projecting worldwide sales of $4.4 billion by 2030 and peak sales of $53 billion, given its potential advantages over Keytruda, which generated $29.5 billion in revenue last year [7][8]. - The company’s market cap is currently $14 billion, and it has plans to target additional indications, with patent exclusivity for ivonescimab lasting until 2039, providing a long window for revenue generation [6][8][9]. Group 2: Madrigal Pharmaceuticals - Madrigal Pharmaceuticals received FDA approval for Rezdiffra, the first medication for metabolic dysfunction-associated steatohepatitis (MASH), addressing a significant unmet medical need linked to obesity [10]. - Rezdiffra generated $287.3 million in revenue in the third quarter, reflecting a 35% quarter-over-quarter increase and a 362% rise year-over-year, with 29,500 patients currently on the medication [11][12]. - The company is expanding its market reach and seeking label expansions for Rezdiffra, with patent protection lasting until 2045 in the U.S., indicating strong future growth potential despite competition [14][15][16].